There is still time to join us on a sign on action letter to the FDA regarding it’s judgement to delay access to the prostate cancer treatment, Provenge, at www.malecare.com With more new drugs set for FDA consideration this summer, a strong showing of Prostate Cancer patients is vital. Please take a look and if [...]
Spectrum Pharmaceuticals announces that the FDA's Oncology Drug Advisory Committee (ODAC) will review their very promising investigational drug Satraplatin for the Treatment of Hormone Refractory Prostate Cancer. The hearing will be held on July 24, 2007. This is very exciting, especially in light of the FDA’s surprising failure to approve Provenge. A quick review of [...]
In today’s Wall Street Journal there is a fantastic opinion piece written by Dr. Mark Thornton, Black Wednesday at the FDA. Dr. Thornton points out that not only did the FDA not approve Provenge last Wednesday, but also it failed to approve Junovan, a immunological drug designed to treat young children with a rare bone [...]
The Wall Street Journal's health blog has exploded with comments about the recent article about the FDA and Provenge. Their piece along with the comments are a must read. You can see the blog at: The Wall Street Journal Health Blog Please don't forget to www.malecare.com and sign our letter to the FDA. Our letter [...]
There is a sign on action letter to the FDA regarding it's CR letter on Provenge, at www.malecare.com Please take a look and if you agree, sign on. Also, please help get the word out about this, as we will mail this letter and its signatories on May 18, 2007.